Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583

Abstract

Tables

Table 2. Analysis of risk factors among the two groups of patients who underwent PDT between January 2017 and March 2024: newly diagnosed (n = 74) and recurrent (n = 97).

	Newly Diagnosed				Recurrence
	Hazard Ratio (95% CI)	p-Value	Hazard Ratio (95% CI)	p-Value	Hazard Ratio (95% CI)	p-Value	Hazard Ratio (95% CI)	p-Value
Age	1.02 (0.99–1.04)	0.26	1.02 (0.99–1.05)	0.27	1.01 (0.99–1.03)	0.22	2.03 (0.81–5.93)	0.50
Male vs. female sex	1.35 (0.62–2.94)	0.44			1.08 (0.62–1.88)	0.45
KPS	0.98 (0.95–1.00)	0.097	0.96 (0.93–0.99)	0.01	0.09 (0.02–0.33)	0.0003	0.96 (0.95–0.99)	0.0008
Alb	1.51 (0.51–4.48)	0.45	3.68 (1.05–13.76)	0.047	2.22 (0.88–5.84)	0.090	2.13 (0.81–5.93)	0.13
Total cholesterol	1.00 (0.98–1.01)	0.59			1.00 (0.99–1.01)	0.40
Benzodiazepine	2.36 (0.81–6.88)	0.15	3.06 (0.96–9.76)	0.059	0.77 (0.34–1.72)	0.52	0.77 (0.34–1.74)	0.52
Smoking	1.57 (0.70–3.53)	0.29	1.58 (0.67–3.73)	0.3	1.07 (0.64–1.79)	0.80	1.21 (0.67–2.19)	0.53
Localization
Temporal vs. not temporal	0.50 (0.22–1.11)	0.079			1.00 (0.56–1.78)	0.99
Frontal vs. not frontal	1.14 (0.51–2.56)	0.75			0.72 (0.43–1.20)	0.20
Parietal vs. not parietal	1.32 (0.53–3.31)	0.56			1.36 (0.72–2.53)	0.35

Table 3. Comparison between the newly diagnosed and recurrent groups based on median tissue TS concentration.

	Newly Diagnosed			Recurrence
	Mean TS Concentration≤0.16333	Mean TS Concentration>0.16333		Mean TS Concentration≤0.0883	Mean TS Concentration>0.0883
	n = 2151.2 (%)	n = 2048.8 (%)	p-Value	n = 2151.2 (%)	n = 2048.8 (%)	p-Value
Male vs. female	13 (31.7%)/8 (19.5%)	13 (31.7%)/7 (17.1%)	0.837	13 (31.7%)/8 (19.5%)	14 (34.2%)/6 (14.6%)	0.5843
Age, mean ± SD	60.7 ± 12.2	61.3 ± 11.9	0.884	47.6 ± 14.2	53.6 ± 10.5	0.5843
Left vs. right (excluded bilateral case)	11 (31.4%)/7 (20.0%)	6 (17.1%)/11 (31.4%)	0.1245	10 (26.3%)/9 (23.7%)	6 (15.8%)/13 (34.2%)	0.1869
Pathological diagnosis
Mean MIB-1 ± SD	28.9 ± 11.9	22.1 ± 11.5	0.0607	21.3 ± 15.4	22.0 ± 15.5	0.8886
ATRX intact vs. loss	20 (51.2%)/0 (0%)	18 (46.2%)/1 (2.6%)	0.226	12 (30.8%)/7 (18.0%)	16 (39.0%)/4 (9.7%)	0.2407
P53 (+) vs. (−)	4 (9.76%)/17 (41.5%)	6 (14.6%)/14 (34.2%)	0.4134	6 (15.0%)/14 (35.0%)	7 (17.0%)/13 (31.7%)	0.7356
IDH (+) vs. (−)	0 (0%)/21 (51.2%)	1 (2.4%)/19 (46.3%)	0.226	5 (12.5%)/15 (37.5%)	4 (9.7%)/16 (39.0%)	0.7047
Part
Temporal vs. not temporal	7 (17.1%)/14 (34.2%)	9 (22.0%)/11 (26.8%)	0.4435	8 (19.5%)/13 (31.7%)	5 (12.2%)/15 (36.6%)	0.366
Frontal vs. not frontal	11 (26.8%)/10 (24.4%)	8 (19.5%)/12 (29.3%)	0.4261	7 (17.1%)/14 (34.2%)	8 (19.5%)/12 (29.3%)	0.6577
Parietal vs. not parietal	2 (4.9%)/19 (46.3%)	2 (4.9%)/18 (43.9%)	0.959	5 (12.2%)/16 (39.0%)	5 (12.2%)/15 (36.6%)	0.9293

Full text

Error in Table

In the original publication [1], there were mistakes in a part of Table 2, Section 2.5, and the label of Table 3. In Table 2, errors present in the data shown under “Recurrence” were identical to those under “Newly Diagnosed”. The corrected Table 2 appears below.

The values in Section 2.5 of the text did not match those in Table 3. We have replaced the first paragraph in Section 2.5 with the paragraph below, in which the numerical values have been corrected, as shown in Table 3. In addition, the label of the right-hand group in Table 3 was incorrect; the correct label is “Recurrence.” The corrected Table 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

2.5. Analysis of Clinical Factors in the High vs. Low Intratumoral TS Concentration Groups

Among the 82 patients for whom intratumoral TS concentration was measured, the newly diagnosed group consisted of 41 patients (high concentration, 51.2%; low concentration, 48.8%) with a mean age of 60.7 years (SD: 12.2 years) and 61.3 years (SD: 11.9 years), respectively.

Similarly, the recurrent group included 41 patients (high concentration, 51.2%; low concentration, 48.8%) with a mean age of 47.6 years (SD: 14.2 years) and 53.6 years (SD: 10.5 years), respectively.

No significant differences in age or sex were observed between the high- and low-concentration groups (age, Newly Diagnosed p = 0.884 and Recurrence p = 0.5843, and sex, Newly Diagnosed p = 0.837 and Recurrence p = 0.5843, respectively). Additionally, no significant differences were found in tumor location, genetic mutations, benzodiazepine use, or smoking history, suggesting that no specific factors were associated with TS concentrations (Table 3).